Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7889657 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7885705 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7885443 | 0.90 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7883371 | 0.90 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7014225 | 0.90 | SMN1; SMN2 (0.43) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7885754 | 0.90 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7887890 | 0.88 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7878605 | 0.88 | OPRL1 (0.52) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7886394 | 0.88 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 | |
| SCHEMBL7885289 | 0.87 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642247-B2 | Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
| CN-1110497-C | Di- Or triaza-spiral [4,5] decane derivative | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | CN | disclosed |
| CN-1107066-C | Diaza-spiro [3,5] nonane derivatives | HOFFMANN LA ROCHE (CH) | 2003-04-30 | — | — | CN | disclosed |
| EP-0963985-B1 | Di-or triaza-spiro(4,5)decane derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | EP | disclosed |
| EP-0970957-B1 | Diaza-spiro[3,5] nonane derivatives | HOFFMANN LA ROCHE (CH) | 2001-08-16 | — | — | EP | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| US-6113527-A | 3,3-BIS-HYDROXYMETHYL-7-(CIS-4-ISOPROPYL-CYCLOHEXYL)-1-PHENYL -1,7-DIAZA-SPIRO-(3.5)NONANE-2-ONE, FOR EXAMPLE; AGONISTS OF THE ORPHANIN FQ (OFQ) RECEPTOR; USEFUL IN THE TREATMENT OF PSYCHIATRIC, NEUROLOGICAL AND PHYSIOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-6071925-A | ANTIDEPRESSANTS, ANTICONVULSANTS OR ANTIANXIETY AGENTS, ALSO FOR TREATMENT OF MEMORY LOSS IN ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| CN-1244528-A | Di- Or triaza-spiral [4,5] decane derivative | HOFFMANN LA ROCHE (CH) | 2000-02-16 | — | — | CN | disclosed |
| CN-1242366-A | Diaza-spiro [3,5] nonane derivatives | HOFFMANN LA ROCHE (CH) | 2000-01-26 | — | — | CN | disclosed |
| EP-0970957-A1 | Diaza-spiro[3,5] nonane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| EP-0963985-A2 | Di-or triaza-spiro(4,5)decane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | OPRL1 36/4885OPRM1 152/4885OPRK1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.